Kyverna Therapeutics, Inc.KYTXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-16.12%
↓ 100% below average
Average (11q)
10122.99%
Historical baseline
Range
High:121456.33%
Low:-99.87%
Volatility
1200.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -16.12% |
| Q2 2025 | -4.32% |
| Q1 2025 | 13.71% |
| Q4 2024 | 12.77% |
| Q3 2024 | 6.85% |
| Q2 2024 | 121456.33% |
| Q1 2024 | -99.87% |
| Q4 2023 | 25.79% |
| Q3 2023 | 31.13% |
| Q2 2023 | 19.45% |
| Q1 2023 | 30.15% |
| Q4 2022 | 0.00% |